These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 38250884)

  • 1. DNA Vaccines: Their Formulations, Engineering and Delivery.
    Kozak M; Hu J
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.
    Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD
    Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies.
    Liu MA
    Vaccines (Basel); 2019 Apr; 7(2):. PubMed ID: 31022829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.
    Suschak JJ; Williams JA; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):2837-2848. PubMed ID: 28604157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development.
    Kozak M; Hu J
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of immunomodulators on the response induced by vaccines against autoimmune diseases.
    Marciani DJ
    Autoimmunity; 2017 Nov; 50(7):393-402. PubMed ID: 28906131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2.
    Salleh MZ; Norazmi MN; Deris ZZ
    PeerJ; 2022; 10():e13083. PubMed ID: 35287350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines.
    Han X; Alameh MG; Butowska K; Knox JJ; Lundgreen K; Ghattas M; Gong N; Xue L; Xu Y; Lavertu M; Bates P; Xu J; Nie G; Zhong Y; Weissman D; Mitchell MJ
    Nat Nanotechnol; 2023 Sep; 18(9):1105-1114. PubMed ID: 37365276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2.
    Neeli P; Chai D; Wang X; Sobhani N; Udeani G; Li Y
    iScience; 2023 Jul; 26(7):107120. PubMed ID: 37361876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering immunity via skin-directed drug delivery devices.
    Polaka S; Makwana V; Vasdev N; Sheth A; Rajpoot K; Sengupta P; Tekade RK
    J Control Release; 2022 May; 345():385-404. PubMed ID: 35283256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine.
    Zuckermann FA; Martin S; Husmann RJ; Brandt J
    Adv Vet Med; 1999; 41():447-61. PubMed ID: 9890035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.